Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation

Clinical Pharmacology and Therapeutics

Volumn 74, Issue 4, 2003, Pages 326-333

  Palovaara, Sanna ^a   Pelkonen, Olavi ^b   Uusitalo, Jouko ^b   Lundgren, Stefan ^c   Laine, Kari ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CYTOCHROME P450 2B6; DESOGESTREL PLUS ETHINYLESTRADIOL; DRUG METABOLITE; ESTRADIOL VALERATE PLUS NORGESTREL; HYDROBUPROPION; HYDROXYBUPROPION; ORAL CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CATALYSIS; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HYDROXYLATION; ENZYME INACTIVATION; ENZYME INHIBITION; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; MEASUREMENT; METHODOLOGY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REACTION ANALYSIS;

ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BUPROPION; CONTRACEPTIVES, ORAL; CROSS-OVER STUDIES; DESOGESTREL; DOPAMINE UPTAKE INHIBITORS; ESTRADIOL; ETHINYL ESTRADIOL; FEMALE; HALF-LIFE; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROXYLATION; LEVONORGESTREL; METABOLIC CLEARANCE RATE; OXIDOREDUCTASES, N-DEMETHYLATING;

EID: 0141706942     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00202-9     Document Type: Article

References (39)

1. Guengerich FP. Metabolism of 17 alpha-ethynylestradiol in humans. Life Sci 1990;47:1981-8.
2. Guengerich FP. Mechanism-based inactivation of human liver microsomal cytochrome P-450 by gestodene. Chem Res Toxicol 1990;3:363-71.
3. Back DJ, Houlgrave R, Tjia JF, Ward S, Orme ML. Effect of the progestogens, gestodene, 3-ketodesogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes. J Steroid Biochem Mol Biol 1991;38:219-25.
4. Balogh A, Klinger G, Henschel L, Börner A, Vollanth R, Kuhnz W. Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. Eur J Clin Pharmacol 1995;48:161-6.
5. Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol 1985;28:425-8.
6. Slayter KL, Ludwig EA, Lew KH, Middleton E Jr, Ferry JJ, Jusko WJ. Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1996;59:312-21.
7. Stoehr GP, Kroboth PD, Juhl RP, Wender DB, Phillips JP, Smith RB. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clin Pharmacol Ther 1984;36:683-90.
8. Hägg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 2001;51:169-73.
9. Laine K, Tybring G, Bertilsson L. No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured, by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin Pharmacol Ther 2000;68:151-9.
10. Kroboth PD, Smith RB, Stoehr GP, Juhl RP. Pharmacodynamic evaluation of the benzodiazepine-oral contraceptive interaction. Clin Pharmacol Ther 1985;38:525-32.
11. Scavone JM, Greenblatt DJ, Locniskar A, Shader RI. Alprazolam pharmacokinetics in women on low-dose oral contraceptives. J Clin Pharmacol 1988;28:454-7.
12. Belle DJ, Callaghan JT, Gorski JC, Maya JF, Mousa O, Wrighton SA, et al. The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol 2002;53:67-74.
13. Pollock BG, Wylie M, Stack JA, Sorisio DA, Thompson DS, Kirshner MA, et al. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. J Clin Pharmacol 1999;39:936-40.
14. Laine K, Palovaara S, Tapanainen P, Manninen P. Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy. Clin Pharmacol Ther 1999;66:602-8.
15. Gorski JC, Wang Z, Haehner-Daniels BD, Wrighton SA, Hall SD. The effect of hormone replacement therapy on CYP3A activity. Clin Pharmacol Ther 2000;68:412-7.
16. Krecic-Shepard ME, Barnas CR, Slimko J, Jones MP, Schwartz JB. Gender specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J Clin Pharmacol 2000;40:219-30.
17. Ball SE, Forrester LM, Wolf CR, Back DJ. Differences in the cytochrome P-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17α-ethinyloestradiol. Biochem J 1990;267:221-6.
18. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
19. Mimura M, Baba T, Yamazaki H, Ohmori S, Inui Y, Gonzalez FJ, et al. Characterization of cytochrome P-460 2B6 in human liver microsomes. Drug Metab Dispos 1993;21:1048-56.
20. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, et al. Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 1999;9:295-306.
21. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000;28:1176-83.
22. Roy P, Yu LJ, Crespi CL, Waxman DJ. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 1999;27:655-66.
23. Court MH, Duan SX, Hesse LM, Venkatakrishnan K, Greenblatt DJ. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology 2001;94:110-9.
24. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999;27:1488-95.
25. Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C19 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2002; 30:853-8.
26. CYP2B6 allele nomenclature. Available at http://www. imm.ki.se/CYPalleles/cyp2b6.htm. Accessed April 30, 2003.
27. Xie H-J, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 2003;3:53-61.
28. Kent UM, Mills DE, Rajnarayanan RV, Alworth WL, Hollenberg PF. Effect of 17-α-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. J Pharmacol Exp Ther 2002;300:549-58.
29. Holm KJ, Spencer CM. Bupropion. A review of its use in the management of smoking cessation. Drugs 2000;59: 1007-24.
30. Posner J, Bye A, Dean K, Peck AW, Whiteman PD. The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses. Eur J Clin Pharmacol 1985;29:97-103.
31. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 2000;28:1222-30.
32. Jinno H, Tanaka-Kagawa T, Ohno A, Makino Y, Matsushima E, Hanioka N, et al. Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 2003;31:398-403.
33. Edwards RJ, Price RJ, Watts PS, Renwick AB, Tredger JM, Boobis AR, et al. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 2003;31:282-8.
34. Ketter TA, Jenkins JB, Schroeder DH, Pazzaglia PJ, Marangeli LB, George MS, et al. Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 1995;15:327-33.
35. Eugster HP, Probst M, Wurgler FE, Sengstag C. Caffeine, estradiol, and progesterone interact with human CYP1A1 and CYP1A2. Evidence from cDNA-directed expression in Saccharomyces cerevisiae. Drug Metab Dispos 1993;21:43-9.
36. Badawi AF, Cavalieri EL, Rogan EG. Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol. Metabolism 2001;50:1001-3.
37. Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 2000;59:961-72.
38. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395-401.
39. Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, Hawk L, et al. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 2002; 12:627-34.